VitK拮抗剂是目前针对血栓栓塞性疾病广泛应用的抗凝药物,但随着新型口服抗凝药(noval oral anticoagulants,NOACs)的问世,起效快、效果佳等优点使其成为抗凝新选择.但NOACs所致的大出血,用传统的止血方式效果十分有限,因此NOACs相关拮抗剂成为研究的焦点.2015年10月以Idarucizumab为首的NOACs特异性拮抗剂已被美国FDA批准上市,另两种颇有前景的Andexanet alfa及Ciraparantag(Aripazine/PER977)也正处于研究的热点,本文综述了3种NOACs特异性拮抗剂的药理作用及有关问题.%Vitamin K antagonists (VKA) are the most widely used anticoagulant drugs for thromboem-bolic disease. As the noval oral anticoagulants (NOACs) have been published, it's gradually becoming a new choice of anticoagulant therapy for their characteristics of working fast and effectively. However, the traditional staunching methods are quite limited for the dramatic bleeding associated with NOACs. Therefore many researches are focused on the specific antidotes to reserve the anticoagulant effect of NOACs. Idaru-cizumab, approved by FDA in October 2015, and other promising antagonists such as Andexanet alfa and Ciraparantag (Aripazine/PER977) are still under study. This review summarizes the pharmacologic actions and related issues of the above specific antagonists.
展开▼
